$65.57 -0.58 (-0.88%)
11/6/2009 4:00 PM

Beckman Coulter, Inc. (BEC)

CAPS Rating: 5 out of 5

The Company is a manufacturer of biomedical testing instrument systems, tests and supplies that simplify and automate laboratory processes.

Current Price $65.57 Mkt Cap $4.49B
Open $65.78 P/E Ratio 25.54
Prev. Close $66.15 Div. (Yield) 0.72 (1.10%)
Daily Range $65.16 - $66.47 Volume 628,114
52-Wk Range $35.94 - $71.57 Avg. Daily Vol. 560,000

BEC News and Commentary

Caps

How do you think BEC will perform vs the S&P 500?

Add Stock to Watchlist

All Members

84 Outperform
7 Underperform
 

All-Star Members

27 Outperform
1 Underperform
 

Wall Street

10 Outperform
0 Underperform
 

Top BEC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

corpblues (98.61)
Submitted March 03, 2009

Not sure if I agree with Dorsey on this one but I'll step out there with monopoly money.

Beckman Coulter (BEC). This mid-size health-care firm is an attractive target for several reasons. For starters, around 80% of its revenue comes from… More

0 Comments | Reply | Report this Post

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

BEC VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about BEC.

Recs

0
Member Avatar sportybostonian (33.91) Submitted: 5/5/2009 4:07:27 PM : Outperform Start Price: $54.04 BEC Score: +3.27

Solid recurring revenue. Should also benefit from stimulus grants.

Report this Post 0 Comments | Reply | Permalink

Recs

1
Member Avatar corpblues (98.61) Submitted: 3/3/2009 12:36:38 PM : Outperform Start Price: $40.43 BEC Score: +7.36

Not sure if I agree with Dorsey on this one but I'll step out there with monopoly money.

Beckman Coulter (BEC). This mid-size health-care firm is an attractive target for several reasons. For starters, around 80% of its revenue comes from recurring sources, such as the reagents used in the testing equipment Beckman sells to hospital labs. The firm also has a key unit focused on modern diagnostic technologies that's growing 15% to 20% a year, which is considered light speed in this mature industry.

Finally, Beckman, whose shares are trading at a modest P/E of around 14, is one of the last pure-play medical testing firms left standing. So it would be a logical target for a large player looking to enter this health-care niche.

Pat Dorsey is the director of equity research for Morningstar.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar TMFHelical (98.37) Submitted: 1/28/2009 10:38:20 AM : Outperform Start Price: $47.50 BEC Score: +12.30

Increased NIH spending should be a benefit for those companies whose product support biotechnology research. They have been beaten down with the market but maintain strong fundamentals as a group.

Report this Post 0 Comments | Reply | Permalink
View All 9 Pitches »

Leaderboard

Find the members with the highest scoring picks in BEC.

Score Leader

steinny11

steinny11 (20.56) Score: +35.73

The Score Leader is the member with the highest score across all their picks in BEC.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
steinny11 20.56 9/13/2006 Outperform 3M $53.60 +22.34% -13.40% +35.73
ArtfullDodger2 55.33 12/13/2006 Outperform 3Y $57.52 +14.00% -20.05% +34.05
slash32is4 75.78 12/12/2006 Outperform NS $57.41 +14.21% -19.75% +33.96
OSUChad 83.92 10/16/2006 Outperform 1Y $55.97 +17.15% -16.70% +33.86
danslip < 20 10/18/2006 Outperform 1Y $56.26 +16.55% -17.08% +33.62
darval 69.45 10/6/2006 Outperform 3Y $55.63 +17.87% -15.69% +33.56 1 Comment
Nimamc < 20 12/11/2006 Outperform 3W $57.81 +13.42% -19.84% +33.26
3st3 96.16 1/9/2009 Outperform NS $42.90 +52.84% +19.60% +33.24
michjoff < 20 10/2/2006 Outperform 3M $55.74 +17.64% -14.83% +32.47
Unperdido < 20 1/8/2007 Outperform 1Y $58.10 +12.86% -19.24% +32.10
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackRWBaird 85.02 7/31/2009 Outperform NS $60.05 +9.20% +9.12% +0.08
TrackBarclaysCap 86.02 3/19/2009 Outperform NS $48.59 +34.96% +34.71% +0.25
TrackOppenheimer 26.63 5/29/2008 Outperform NS $67.65 -3.07% -20.09% +17.02
TrackLeerinkSwan 84.26 4/30/2008 Outperform NS $67.52 -2.89% -20.38% +17.49
TrackBofASec 93.50 12/10/2007 Outperform NS $70.33 -6.77% -25.81% +19.04
TrackRichAster 91.10 9/30/2007 Outperform NS $71.95 -8.86% -26.44% +17.57 2 Comments
TrackEdwardOwens 98.26 9/30/2007 Outperform NS $71.95 -8.86% -26.44% +17.57 3 Comments
TrackDreman 89.07 9/30/2007 Outperform NS $71.95 -8.86% -26.44% +17.57 2 Comments
TrackRBCCapMkts 81.74 5/3/2007 Outperform NS $63.37 +9.38% +2.45% +6.94 10/31/2007 @ $69.32
TrackJimCramer < 20 10/13/2006 Outperform 3W $55.86 +17.37% -16.66% +34.04
TrackLazardCapit < 20 10/4/2006 Outperform NS $55.46 +18.24% -14.49% +32.72

Featured Broker Partners